AbbVie Showcases New Data Supporting Premier Gastroenterology Portfolio at 2024 Digestive Disease Week
AbbVie (NYSE: ABBV) announced it will present 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, occurring May 18-21 in Washington, D.C., and virtually. “At DDW, AbbVie is…
Understanding the Difference Between IBS and IBD
Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are often confused, as their names and symptoms—such as diarrhea and abdominal pain—are similar. However, these gastrointestinal (GI) disorders are fundamentally…
Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction and Safety
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials for once-weekly insulin efsitora alfa (efsitora) in adults with type 2…
Nucleai Names Vikas Ahuja as VP of Strategic Partnerships, Driving Diagnostic Deployment and Scale-Up
A spatial AI biomarker company specializing in deciphering cellular conversations and mapping cellular interactions within tissue samples to predict therapeutic outcomes has announced the expansion of its executive leadership team.…
Accenture’s Investment in Turbine to Boost AI-Powered Cell Simulations for Biopharma R&D
Accenture Ventures, a strategic arm of Accenture (NYSE: ACN), recently announced its investment in Turbine, a forward-thinking predictive simulation company dedicated to interpreting human biology. This investment aims to bolster…
Encouraging Phase Ib Findings from Genentech on CT-388, a Dual GLP-1/GIP Receptor Agonist, in Individuals Battling Obesity
Genentech, a member of the Roche Group, disclosed favorable outcomes from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist aimed at addressing obesity and type 2…
SunLink Health Systems, Inc. Reveals Performance for Fiscal Q3 2024
SunLink Health Systems, Inc. (NYSE American: SSY) disclosed today a loss from continuing operations of $824,000 (equating to a loss of $0.12 per fully diluted share) for its third fiscal…
OmniAb Showcases xPloration® High-Throughput Single B-cell Screening Data at 20th Annual PEGS Boston Summit
OmniAb has announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, held at the Omni Hotel. Earlier today, the company presented an…
enGene Elects Paul Hastings and Wouter Joustra to its Board of Directors
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company with its lead non-viral program EG-70 undergoing pivotal trials for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced the election of…
Omeros Corporation Reports First Quarter 2024 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders such as…
Gate Neurosciences to Present New Synaptic Function Molecule Research at 2024 ASCP Annual Meeting
A clinical-stage biotechnology company focused on precision medicine to develop next-generation neuroscience therapies announced its upcoming activities at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP)…
UCSF, in Collaboration with Nutcracker Therapeutics, Unveils Groundbreaking Prostate Cancer Data at AAI 2024
Nutcracker Therapeutics, a biotechnology company focused on developing transformative RNA therapies through its proprietary technology platform, announced the presentation of key prostate cancer antigen research by its partners at the…